This TKI inhibits HER2 and epidermal growth factor receptor type 1 (EGFR1) and exerts its anti-tumor effects by blocking the HER2 signaling by competing with the antitumor ATP [58]. This evidence concerns the gene ERBB2 and neoplasm.